Suter Philipp, Grobéty Thomas, Vaucher Julien, Grandmaison Gaël
Division of Internal Medicine, Fribourg Hospital and University of Fribourg, Fribourg, Switzerland.
Department for Pulmonology, Allergology and Clinical Immunology, Inselspital, University Hospital Bern, Bern, Switzerland.
Int J Chron Obstruct Pulmon Dis. 2025 Apr 4;20:957-969. doi: 10.2147/COPD.S512880. eCollection 2025.
PURPOSE: Effective treatment of chronic obstructive pulmonary disease (COPD) primarily relies on treatment delivered through inhaler devices. The effectiveness of dry powder inhalers is compromised by insufficient peak inspiratory flow (PIF). Understanding the evolution of PIF during hospitalization is crucial for optimizing inhaler selection and improving patient outcomes. PATIENTS AND METHODS: A prospective monocentric observational study was conducted at Fribourg Hospital, Switzerland, from August 2022 to December 2022. PIF was assessed at hospital admission and discharge in all patients with COPD admitted to the internal medicine division. The primary outcome was the evolution of maximum PIF at a fixed medium-low resistance (R2) during hospitalization. Secondary outcomes included the variation of PIF in the intra-assessment evaluation and transitioning between sufficient and insufficient PIF. RESULTS: Forty-nine patients were enrolled, 61% were men and 65% experienced an acute COPD exacerbation (AECOPD). The maximum PIF for R2 increased from 64.8 ± 17.2 L/min at admission to 70.7 ± 17.9 L/min at discharge, showing a 5.9 L/min improvement (95% CI: 2.4-9.5, p < 0.01). A hospitalization >5 days in patients hospitalized for an AECOPD is associated with a higher increase in PIF (p < 0.05). In the intra-assessment measurement, we observed an increase in PIF in the successive measurements (p < 0.01). CONCLUSION: Hospitalized patients with COPD experienced a significant increase in PIF during their stay. These results appear to be independent of the reason for hospitalization but need to be confirmed with a larger sample. Nevertheless, these findings underscore the importance of regular PIF assessment and influence inhaler selection.
目的:慢性阻塞性肺疾病(COPD)的有效治疗主要依赖于通过吸入装置进行的治疗。干粉吸入器的有效性因吸气峰值流速(PIF)不足而受到影响。了解住院期间PIF的变化对于优化吸入器的选择和改善患者预后至关重要。 患者与方法:2022年8月至2022年12月在瑞士弗里堡医院进行了一项前瞻性单中心观察性研究。对内科收治的所有COPD患者在入院时和出院时进行PIF评估。主要结局是住院期间在固定的中低阻力(R2)下最大PIF的变化。次要结局包括评估内PIF的变化以及PIF在足够和不足之间的转变。 结果:共纳入49例患者,61%为男性,65%经历了慢性阻塞性肺疾病急性加重(AECOPD)。R2时的最大PIF从入院时的64.8±17.2升/分钟增加至出院时的70.7±17.9升/分钟,改善了5.9升/分钟(95%置信区间:2.4 - 9.5,p<0.01)。因AECOPD住院>5天的患者PIF升高幅度更大(p<0.05)。在评估内测量中,我们观察到连续测量时PIF有所增加(p<0.01)。 结论:住院的COPD患者在住院期间PIF显著增加。这些结果似乎与住院原因无关,但需要更大样本进行证实。尽管如此,这些发现强调了定期评估PIF的重要性,并对吸入器的选择有影响。
Int J Chron Obstruct Pulmon Dis. 2025-4-4
J Aerosol Med Pulm Drug Deliv. 2024-10
Int J Chron Obstruct Pulmon Dis. 2025-3-25
J Aerosol Med Pulm Drug Deliv. 2025-4
BMJ Open Respir Res. 2025-5-12
Int J Chron Obstruct Pulmon Dis. 2011-2-2
Int J Chron Obstruct Pulmon Dis. 2025-3-8
J Aerosol Med Pulm Drug Deliv. 2024-8
Chronic Obstr Pulm Dis. 2024-3-26
JAMA Netw Open. 2023-12-1
Int J Chron Obstruct Pulmon Dis. 2023
Int J Chron Obstruct Pulmon Dis. 2022